Six physicians at UCLA’s Geffen School of Medicine authored the study and stated that six therapies for heart failure could have prevented that total death figure. The six therapies include angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist, β-blockers, aldosterone antagonists, hydralazine/isorbide dinitrat, implantable cardioverter-defibrillators and cardiac resynchronization therapy.
The research also showed that nearly 2.7 million heart failure patients were eligible for those therapies but did not receive treatment.
Related Articles on Heart Specialties:
Essentia Program Reduces Readmission Rates, Costs for Heart Failure Patients
Study: Tai Chi May Help Improve Quality of Life for Systolic Heart Failure Patients
New Jersey Pilot Program Monitors Heart Patients From Home, Aims to Reduce Hospital Visits
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
